Tag Archive for: NBI.11175568

Nxtera Pharma Ltd
Deal

Nxera Pharma Ltd collects clinical US$35m milestone

Nxera Pharma Ltd has got a Phase II milestone from US licencor Neurocrine Biosciences for its first-in class oral schizophrenia candidate NBI-1117568.

Read more